Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC
Status:
Recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
Exploratory phase II trial of intravenous (IV) Pembrolizumab MK-3475 as second or further
line with advanced Non-small cell Lung Cancer (NSCLC) who have failed to a prior treatment
with anti-PDL1 drug.
Pembrolizumab 200 mg ,Q3W, IV infusion, Day 1 of each 3 week cycle will be administered until
disease progression.